Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34529931

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Oct
First author
Moreau P

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Nov;18(11):676. doi: 10.1038/s41571-021-00563-4.
    note
    Source null
    related pmid
    34545220
    relationship
    Comment in

Authors and identifiers

  1. name
    Moreau P
    type
    Author
  2. name
    Hulin C
    type
    Author
  3. name
    Perrot A
    type
    Author
  4. name
    Arnulf B
    type
    Author
  5. name
    Belhadj K
    type
    Author
  6. name
    Benboubker L
    type
    Author
  7. name
    Béné MC
    type
    Author
  8. name
    Zweegman S
    type
    Author
  9. name
    Caillon H
    type
    Author
  10. name
    Caillot D
    type
    Author
  11. name
    Corre J
    type
    Author
  12. name
    Delforge M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Moreau P
    type
    Author
  2. name
    Hulin C
    type
    Author
  3. name
    Perrot A
    type
    Author
  4. name
    Arnulf B
    type
    Author
  5. name
    Belhadj K
    type
    Author
  6. name
    Benboubker L
    type
    Author
  7. name
    Béné MC
    type
    Author
  8. name
    Zweegman S
    type
    Author
  9. name
    Caillon H
    type
    Author
  10. name
    Caillot D
    type
    Author
  11. name
    Corre J
    type
    Author
  12. name
    Delforge M
    type
    Author
bibliography ids
  1. nci-bib-7be76a9fdaaf21279bcd2286
book metadata
content sha256
c21f4ec70b8fa08303d902cda8bb3c8bb03797dc2aca1827241cc47e18220731
document type
citation
dois
  1. 10.1016/S1470-2045(21)00428-9
electronic publication date
display
2021 Sep 13
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34529931
immutable id
pubmed:34529931@c21f4ec70b8fa08303d902cda8bb3c8bb03797dc2aca1827241cc47e18220731
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1378-1390
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Nov;18(11):676. doi: 10.1038/s41571-021-00563-4.
    note
    Source null
    related pmid
    34545220
    relationship
    Comment in
outcomes validated
false
pmid
34529931
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
9874b0382eb6578c5ecd84e822c2cf051abae425ad71d35f85859d9d78457377
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Oct
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34529931/
title
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice